Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
Black Diamond Therapeutics(US:BDTX) Seeking Alphaยท2025-08-25 15:13Company Overview - Black Diamond Therapeutics (BDTX) is a clinical stage biotechnology firm focused on developing treatments for EGFR-mutated non-small cell lung cancer (NSCLC) [1] Product Development - The main candidate of BDTX is BDTX-1535, also known as Silvertinib, which is currently being investigated in both first line and advanced lines of treatment for NSCLC [1]